Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 May;25(5):e782-e788.
doi: 10.1634/theoncologist.2019-0490. Epub 2019 Dec 18.

An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas

Ming-Huang Chen  1   2 , Wen-Chi Chou  3 , Chin-Fu Hsiao  4 , Shih Sheng Jiang  5 , Hui-Jen Tsai  6   7   8 , Yi-Chang Liu  7 , Chiun Hsu  9 , Yan-Shen Shan  10 , Yi-Ping Hung  1   2 , Chia-Hsun Hsich  3 , Chao-Hua Chiu  1   2 , Ta-Chih Liu  11 , Shih-Feng Cho  7 , Tsang-Wu Liu  5 , Yee Chao  1   2
Affiliations
Clinical Trial

An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas

Ming-Huang Chen et al. Oncologist. 2020 May.

Abstract

Background: The discovery of effective therapeutic options for treating metastatic poorly differentiated neuroendocrine carcinoma (NEC) after prior platinum-based chemotherapy remains elusive. This study analyzed the efficacy of TLC388 (Lipotecan) Hydrochloride, a novel camptothecin analog, for pretreated patients with metastatic NEC.

Methods: This single-arm, two-stage, phase II clinical trial was conducted at four community and academic centers in Taiwan. Patients aged 20 years or older with confirmed metastatic NEC and who had received prior systemic therapy with etoposide plus cisplatin were enrolled between July 2015 and May 2018. Patients received 40 mg/m2 of TLC388 intravenously on days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxic effects. Gene mutations were analyzed by next-generation sequencing.

Results: Twenty-three patients with a median age of 61 (range, 44-73) years, 18 of whom were men (78%), were enrolled. Patients received a median of 2 (range, 0-6) treatment cycles. Among 20 evaluable patients, 3 patients exhibited stable disease and no patient experienced a complete or partial remission, resulting in a disease control rate of 15%. Median progression-free survival was 1.8 (95% confidence interval [CI], 0.4-15) months, and the median overall survival was 4.3 (95% CI, 1.7-15) months. The most common treatment-related hematologic adverse events at grade 3 or higher were leukopenia (22.7%), anemia (31.8%), and thrombocytopenia (18.2%). The most frequent mutated genes in 35 patients with NEC were ARSA, DPYD, HEXB, BRCA1, HPD, MYBPC3, BBS2, IL7R, HSD17B4, and PRODH.

Conclusion: TLC388 demonstrates limited antitumor activity in metastatic NEC. ClinicalTrials.gov identifier: NCT02457273.

Implications for practice: Poorly differentiated neuroendocrine carcinomas (NECs) are rare and aggressive. Currently, effective therapeutic options for treating metastatic poorly differentiated NECs beyond platinum-based chemotherapy remain elusive. In this single-arm, multicenter, phase II study, 23 patients with NEC were enrolled and received TLC388 (Lipotecan) Hydrochloride, which is a novel camptothecin analog. The results demonstrated the disease control rate of 15%, the median progression-free survival of 1.8 (95% confidence interval [CI], 0.4-15) months, and the median overall survival of 4.3 (95% CI, 1.7-15) months. Most importantly, several novel genetic mutations and pathways were identified. These results offer the opportunity to develop future treatment strategies in this rare cancer.

Keywords: Genetic profiles; Neuroendocrine carcinoma; TLC-388; Topotecan.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

Figures

Figure 1
Figure 1
Patient disposition.Abbreviation: AE, adverse event.
Figure 2
Figure 2
Kaplan‐Meier analyses of survival outcomes in patients with poorly differentiated neuroendocrine carcinomas. (A): Progression‐free survival. (B): Overall survival.Abbreviations: OS, overall survival; PFS, progression‐free survival
Figure 3
Figure 3
The landscape of genetic mutations with more than 50% in the 35 samples of poorly differentiated neuroendocrine carcinoma.
See this image and copyright information in PMC

References

    1. Ahlman H, Nilsson O, McNicol AM et al. Poorly‐differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendocrinology 2008;87:40–46. - PubMed
    1. Nilsson O, Van Cutsem E, Delle Fave G et al. Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology 2006;84:212–215. - PubMed
    1. Majhail NS, Elson P, Bukowski RM. Therapy and outcome of small cell carcinoma of the kidney: Report of two cases and a systematic review of the literature. Cancer 2003;97:1436‐1441. - PubMed
    1. Mills SE, Cooper PH, Garland TA et al. Small cell undifferentiated carcinoma of the larynx. Report of two patients and review of 13 additional cases. Cancer 1983;51:116–120. - PubMed
    1. Rindi G, Klöppel G, Alhman H et al. TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system. Virchows Arch 2006;449:395–401. - PMC - PubMed

Publication types

Associated data